Recursion Pharmaceuticals, Inc. Share Price

Equities

RXRX

US75629V1044

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/04/2024 BST 5-day change 1st Jan Change
7.94 USD +3.12% Intraday chart for Recursion Pharmaceuticals, Inc. +4.89% -19.47%
Sales 2024 * 53.92M 4.33B Sales 2025 * 60.67M 4.87B Capitalization 1.83B 147B
Net income 2024 * -411M -32.99B Net income 2025 * -481M -38.61B EV / Sales 2024 * 28 x
Net cash position 2024 * 322M 25.84B Net cash position 2025 * 279M 22.37B EV / Sales 2025 * 25.6 x
P/E ratio 2024 *
-4.53 x
P/E ratio 2025 *
-4.1 x
Employees 500
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.33%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.12%
1 week+4.89%
Current month-20.36%
1 month-24.31%
3 months-25.38%
6 months+39.30%
Current year-19.47%
More quotes
1 week
7.14
Extreme 7.135
8.27
1 month
7.14
Extreme 7.135
10.91
Current year
7.14
Extreme 7.135
15.74
1 year
4.54
Extreme 4.54
16.75
3 years
4.54
Extreme 4.54
42.81
5 years
4.54
Extreme 4.54
42.81
10 years
4.54
Extreme 4.54
42.81
More quotes
Managers TitleAgeSince
Founder 41 04/11/13
Founder 42 04/11/13
Founder 62 04/11/13
Members of the board TitleAgeSince
Director/Board Member 61 19/03/20
Chairman 60 31/03/20
Founder 62 04/11/13
More insiders
Date Price Change Volume
24/04/24 7.94 +3.12% 7,045,621
23/04/24 7.7 +1.32% 5,111,318
22/04/24 7.6 +3.40% 3,946,342
19/04/24 7.35 -0.68% 4,013,543
18/04/24 7.4 -0.94% 2,862,410

Delayed Quote Nasdaq, April 24, 2024 at 09:00 pm

More quotes
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
7.7 USD
Average target price
13 USD
Spread / Average Target
+68.83%
Consensus